Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 7/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22469704 | 0.86 | MRGPRX4 (0.72) | USP2L3MBTL1MRGPRX4MAPTLMNA | |
| SCHEMBL2961566 | 0.86 | L3MBTL1 (0.60) | USP2L3MBTL1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL27644893 | 0.85 | MRGPRX4 (0.56) | USP2L3MBTL1MRGPRX4MAPTALDH1A1 | |
| SCHEMBL2960598 | 0.85 | L3MBTL1 (0.61) | USP2L3MBTL1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1342540 | 0.84 | USP2 (0.63) | USP2L3MBTL1MRGPRX4MAPTLMNA | |
| SCHEMBL3507291 | 0.83 | USP2 (0.61) | USP2L3MBTL1MAPTALDH1A1MEN1 | |
| SCHEMBL2964389 | 0.83 | L3MBTL1 (0.59) | USP2L3MBTL1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2969396 | 0.83 | L3MBTL1 (0.55) | L3MBTL1CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL3505628 | 0.82 | MRGPRX4 (0.54) | USP2L3MBTL1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2964888 | 0.81 | L3MBTL1 (0.53) | L3MBTL1CYP1A2CYP2C9CYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3792251-B1 | NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS | ELANCO TIERGESUNDHEIT AG (CH) | 2024-02-14 | — | — | EP | disclosed |
| EP-3792251-A1 | NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS | Elanco Tiergesundheit AG (CH) | 2021-03-17 | — | — | EP | disclosed |
| CN-106660961-B | Sulfonylaminobenzamide compounds as anthelmintics | 瑞士伊兰科动物保健有限公司 | 2020-05-05 | — | — | CN | disclosed |
| US-10464889-B2 | Sulfonylaminobenzamide compounds as anthelmintics | ELANCO TIERGESUNDHEIT AG (US) | 2019-11-05 | — | — | US | disclosed |
| US-20180319741-A1 | NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS | ELANCO TIERGESUNDHEIT AG (US) | 2018-11-08 | — | — | US | disclosed |
| US-20170226053-A1 | NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS | NOVARTIS TIERGESUNDHEIT AG (CH) | 2017-08-10 | — | — | US | disclosed |
| EP-3186227-A1 | NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS | Novartis Tiergesundheit AG (CH) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016033341-A1 | NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS | NOVARTIS TIERGESUNDHEIT AG (CH) | 2016-03-03 | — | — | WO | disclosed |
| EP-2990403-A1 | ANTHRANILAMIDES, SULFONAMIDES AND NITRO ANALOGUES DERIVED THEREFROM AS ANTHELMINTICS | Novartis Tiergesundheit AG (CH) | 2016-03-02 | — | — | EP | disclosed |
| US-8338605-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2012-12-25 | — | — | US | disclosed |
| US-20100256139-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2010-10-07 | — | — | US | disclosed |
| EP-1979349-B1 | ANTI-VIRAL COMPOUNDS | ABBOTT LAB (US) | 2010-07-28 | — | — | EP | disclosed |
| US-7763731-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2010-07-27 | — | — | US | disclosed |
| EP-1979349-A2 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2008-10-15 | — | — | EP | disclosed |
| US-20070232645-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-10-04 | — | — | US | disclosed |
| WO-2007076035-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226053-A1 | NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS | PKD2, CATSPER1, PKD1 | USP2 3564/4885L3MBTL1 2578/4885CYP1A2 1297/4885 |
| US-20070232645-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | USP2 2057/4885L3MBTL1 2884/4885CYP1A2 877/4885 |
| US-20100256139-A1 | Anti-Viral Compounds | HAVCR2, MAVS, EIF2AK2 | USP2 2057/4885L3MBTL1 2884/4885CYP1A2 877/4885 |
| US-10464889-B2 | Sulfonylaminobenzamide compounds as anthelmintics | PKD2, CATSPER1, ATP1B2 | USP2 3790/4885L3MBTL1 2117/4885CYP1A2 925/4885 |
| US-20180319741-A1 | NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS | PKD2, CATSPER1, PKD1 | USP2 3564/4885L3MBTL1 2578/4885CYP1A2 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.